Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of
the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and
the Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) inhibitor mAb Ipilimumab will be safe and
feasible and will show preliminary evidence of anti-tumor efficacy and survival in comparison
to historical results following treatment with either agent alone.